Literature DB >> 10577980

Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis.

J F Fries1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10577980      PMCID: PMC1766585          DOI: 10.1136/ard.58.2008.i86

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  The chronic disease data bank model: a conceptual framework for the computer-based medical record.

Authors:  J F Fries
Journal:  Comput Biomed Res       Date:  1992-12

2.  A toxicity index for comparison of side effects among different drugs.

Authors:  J F Fries; P W Spitz; C A Williams; D A Bloch; G Singh; H B Hubert
Journal:  Arthritis Rheum       Date:  1990-01

3.  Toward an understanding of patient outcome measurement.

Authors:  J F Fries
Journal:  Arthritis Rheum       Date:  1983-06

4.  The relative toxicity of nonsteroidal antiinflammatory drugs.

Authors:  J F Fries; C A Williams; D A Bloch
Journal:  Arthritis Rheum       Date:  1991-11

Review 5.  Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis.

Authors:  J F Fries
Journal:  J Rheumatol Suppl       Date:  1996-03

6.  The relative toxicity of disease-modifying antirheumatic drugs.

Authors:  J F Fries; C A Williams; D Ramey; D A Bloch
Journal:  Arthritis Rheum       Date:  1993-03
  6 in total
  5 in total

Review 1.  Appropriate and effective management of rheumatoid arthritis.

Authors:  F C Breedveld; J R Kalden
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

Review 2.  Health economics: implications for novel antirheumatic therapies.

Authors:  A Kavanaugh
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

3.  Combination therapy for rheumatoid arthritis in the era of biologicals.

Authors:  Allan Gibofsky
Journal:  HSS J       Date:  2006-02

Review 4.  Developments in the clinical understanding of rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

5.  Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs.

Authors:  Helga Radner; Josef S Smolen; Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2014-02-21       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.